Savara Inc
corporate_fare Company Profile
Savara Inc (NASDAQ:SVRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for SVRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 9/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SVRA spans 10-Q, 4, 8-K, DEFA14A.
Recent high-impact activity:
- FDA Misses PDUFA Date for Savara's Lead Rare-Lung Drug, No New Timeline Given
- Savara Q3 Loss Widens to $43.0M as MOLBREEVI PDUFA Nears November 22
- Savara Q2 Loss Widens on Commercial Build-Out; FDA Extends MOLBREEVI Review to November
- Savara Q2 Loss Widens to $40.2M as Commercial Prep Costs Surge
- CFO Sells $2.24M in Open Market Shares Following Resignation Announcement
Financial Snapshot
Short Interest & Short Volume
12.94 days to coverFINRA reported short interest of 32,273,605 shares in SVRA as of the October 30, 2026 settlement, a 12.3% increase from the prior period — about 12.9 days to cover at its recent average daily volume. On November 20, 2026, 61.3% of SVRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.